Browsing by Author "Ebru Nur Ay / L-5910-2018"
Now showing items 1-4 of 4
-
Investigation of possible associations between tryptophan/kynurenine status and FOXP3 expression in colorectal cancer
Ay, Ebru Nur; Hakan, Mehmet Tolgahan; Arıkan, Soykan; Demirkol, Şeyda; Doğan, Mehmet Baki; Hepokur, Ceylan Özsoy; Yaylım, İlhan; Akyüz, Filiz; Horozoğlu, Cem (Taylor and Francis, 2022)Tryptophan metabolism in the tumor microenvironment exerts immunosuppressive effects by affecting the anti-tumor functions of immune cells. The immunosuppressive roles of tryptophan and tryptophan metabolites and their ... -
Kalsitriol ve doksorubisin kombinasyonunun MCF7 üzerine olası anti kanser etkilerinin araştırılması
Bildiren, Özge; Cevatemre, Buse; Ay, Ebru Nur; Özen, Güneş; Hepokur, Ceylan; Erkısa Genel, Merve; Ulukaya, Engin (DergiPark, 2018)Amaç: Bu çalışmada amacımız, belirli bir dozun üzerinde kardiyak yan etkileri oldukça fazla olan ve meme kanseri tedavisinde kullanılan kemoterapötiklerden doksorubisinin, tedavide kullanım miktarlarını azaltmayı ve ... -
Silver nanoparticle/capecitabine for breast cancer cell treatment
Hepokur, Ceylan; Kariper, İshak Afşin; Mısır, Sema; Ay, Ebru Nur; Tunoğlu, Servet; Ersez, Mediha Süleymanoğlu; Zeybek, Ümit; Kuruca, Serap Erdem; Yaylım, İlhan (Pergamon-Elsevier Science Ltd, 2019)This study aimed to evaluate antiproliferative and proapoptotic effects of Capecitabine bonded silver particles on human breast cancer cells (MCF-7). Different sizes of Ag NPs (in sizes 5, 10, 15, 30 nm) were synthesized. ... -
Therapeutic targeting of molecular pathways in colorectal cancer
Ay, Ebru Nur (MorionLLC, 2022)Mutations in tumor suppressor genes, cell signaling, and genes associated with DNA repair lead to onset of colorectal cancer (CRC). Even though most CRC patients get clinical benefits from conventional treatments such as ...
